BioSpace News Archive

Anixa Biosciences, Inc., a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, announced the publication of a peer-reviewed journal article in Biomarker Insights.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2020 financial results on Thursday, April 30, 2020, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. an

Agile Therapeutics, Inc., a forward-thinking women’s healthcare company, announced it will report first quarter 2020 financial results after the market close on Tuesday, May 5, 2020.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the appointment of Zafar Qadir as the Company’s General Counsel.

iCAD, Inc. announced it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,562,500 shares of the Company’s common stock at $8.00 per share, pursuant to a registered direct offering.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will release financial results for the first quarter 2020, after the market close on Thursday, April 30, 2020.

Led cellular immunology at AgenTus and recognized expert on the biology and clinical application of Natural Killer T (NKT) cells and other immune cells

Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that it has initiated a Phase 1 clinical trial of its first-in-class antibody SRF388, which targets the immunosuppressive cytokine IL-27.

Establishment Labs Holdings Inc., a medical technology company focused on Women’s Health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended March 31, 2020 after the market closes on Thursday, May 7, 2020, and will host a conference call at 5:00 pm ET that day to discuss those results.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its lead product Berubicin.